These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25571722)

  • 21. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
    Kim HR; Yim HJ; Kang S; Suh SJ; Kim SY; Hyun JJ; Koo JS; Kim JH; Seo YS; Yeon JE; Lee SW; Byun KS; Um SH
    Liver Int; 2015 Mar; 35(3):860-9. PubMed ID: 24905912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Treg cells and HBV genotype on sustained response and drug resistance in the treatment with nucleoside drugs.
    Zhang YR; Li B; Wang CX; Zhou N; Qi W; Li XL; Wu LY; Wei SF; Zhang YD
    Braz J Med Biol Res; 2017 Mar; 50(3):e5796. PubMed ID: 28273209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
    Cheng PN; Chang TT
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis.
    Liu H; Wang X; Wan G; Yang Z; Zeng H
    Am J Med Sci; 2014 Feb; 347(2):131-8. PubMed ID: 23563307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).
    Lee HW; Park JY; Kim BK; Kim MY; Lee JI; Kim YS; Yoon KT; Han KH; Ahn SH
    Clin Mol Hepatol; 2016 Dec; 22(4):443-449. PubMed ID: 27880997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
    Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
    N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
    N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
    Zhang Y; Hu P; Qi X; Ren H; Mao RC; Zhang JM
    Clin Microbiol Infect; 2016 Mar; 22(3):287.e1-9. PubMed ID: 26548508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Chang TT; Chao YC; Gorbakov VV; Han KH; Gish RG; de Man R; Cheinquer H; Bessone F; Brett-Smith H; Tamez R
    J Viral Hepat; 2009 Nov; 16(11):784-9. PubMed ID: 19457141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China.
    Li X; Liu Y; Xin S; Ji D; You S; Hu J; Zhao J; Wu J; Liao H; Zhang XX; Xu D
    Microb Drug Resist; 2017 Jun; 23(4):516-522. PubMed ID: 27792585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
    Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA-DP and γ-interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection.
    Lam YF; Wong DK; Seto WK; To KK; Hung IF; Fung J; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2014 Mar; 29(3):533-9. PubMed ID: 23980639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
    Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
    Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.
    Chen CH; Hung CH; Wang JH; Lu SN; Hu TH; Lee CM
    Clin Microbiol Infect; 2018 Sep; 24(9):997-1003. PubMed ID: 29288020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B.
    Doğan ÜB; Öztürk AB; Akın MS; Yalaki S; Sayan M
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():206-9. PubMed ID: 25910308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B.
    Law ST; Lee MK; Li KK; Mok CK
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):193-8. PubMed ID: 26587867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response.
    Tangkijvanich P; Chittmittraprap S; Poovorawan K; Limothai U; Khlaiphuengsin A; Chuaypen N; Wisedopas N; Poovorawan Y
    J Viral Hepat; 2016 Jun; 23(6):427-38. PubMed ID: 26387494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
    An J; Lim YS; Kim GA; Han SB; Jeong W; Lee D; Shim JH; Lee HC; Lee YS
    BMC Gastroenterol; 2017 Jan; 17(1):15. PubMed ID: 28103819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
    Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.